T. Man Pharmaceutical Public Company Limited, or TMAN, has announced the creation of a New S-Curve, moving into the longevity and wellness hub megatrend, with a target of driving revenue growth to 4 billion baht within the next 3-5 years, up from 2.5 billion baht in 2025. Prapol Thanachotiphan, Chief Executive Officer of TMAN, told InfoQuest that in the first 1-3 years the company will continue to grow from its core business by expanding hospital channels to raise their revenue share to 15-20% from 10% previously, while pushing the Propolis brand to become a full regional and international brand, from its current exports to more than 7 countries, and more than 10 countries across all products. Meanwhile, its OEM contract manufacturing business has grown by more than 100%, and it recently secured a major customer, Berham, in the distribution business for other brands. For the creation of the New S-Curve, the company will launch a new supplement brand at the end of this year, focusing on dietary supplements, vitamins and biotechnology under its own brand, targeting growth of 5-10% per year for this group over the next 5 years, and has assigned its subsidiary Nova Health to accelerate collaboration with leading research institutes to develop health innovations that address longevity, together with external partners.
T Man Pharmaceutical PCLTMAN targets revenue growth to 4 billion baht via hospital channel expansion, Propolis international brand push, and a new supplement brand, driving product demand.
Subsidiary Nova Health is assigned to collaborate with research institutes to develop longevity health innovations.
